FXN and Friedreich ataxia: In our study, we examined the effect of SS-31 treatment on lymphoblasts and fibroblasts derived from FRDA patients and found that SS-31 not only acts as an antioxidant to relieve the oxidative stress, but also increases the protein level of FXN, which would be the fundamental resolution for FRDA patients.